Researchers studied 254 children, 5 to 11 years of age, who had mild-to-moderate persistent asthma. They also had at least one asthma exacerbation, or attack, treated with systemic glucocorticoids in the previous year.
For the study, children were randomly assigned to receive low-dose inhaled glucocorticoids or use a quintupled dose for seven days at the early signs of loss of asthma control.
The study shows rate of severe asthma exacerbations treated with systemic glucocorticoids did not differ significantly between the two groups. Additionally, the following factors did not differ between the groups:
• Time to the first exacerbation
• Rate of treatment failure
• Symptom scores
• Albuterol use during yellow-zone episodes
Researchers found the total glucocorticoid exposure was 16 percent higher in the high-dose group as compared to the low-dose group.
More articles on healthcare quality:
Oregon fines mental health hospital $1.6k for failing to protect workers from patient assaults
Emergency general surgery patients experience high VTE risk
Nonventilator hospital-acquired pneumonia ‘underappreciated’ patient safety issue
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.